Insulet Corp
Stocks making the biggest moves after hours: Dexcom, Coursera, Deckers Outdoor and more
Check out the companies making headlines in after-hours trading. Deckers Outdoor — The footwear company’s stock jumped 8% after Deckers reported fiscal first-quarter earnings of $4.52 per share on revenues of $825 million, exceeding analysts’ expectations for earnings of $3.48 per share on revenues of $808 million. Dexcom — Shares of the medical device company […]
Read More
Stocks producing the greatest moves midday: Novavax, Taiwan Semiconductor, Sweetgreen and extra
Verify out the providers earning headlines in midday trading: Novavax — The biotech organization soared 110% just after saying a multibillion-greenback offer with French drugmaker Sanofi to co-commercialize its Covid vaccine commencing future yr. The firms will also develop blend pictures targeting the coronavirus and flu. Taiwan Semiconductor Production — The chipmaker jumped 5% just […]
Read More
Shares producing the largest moves premarket: Yelp, Sweetgreen, Novavax, Akamai Systems and more
Look at out the corporations producing headlines right before the bell. Akamai Systems — Shares of the cloud enterprise fell a lot more than 10% soon after issuing weak steering for the 2nd quarter. Akamai sees adjusted earnings ranging from $1.51 to $1.56 for each share on income of $967 million to $986 million. Analysts […]
Read More
Shares earning the biggest moves right after hours: Yelp, Sweetgreen, Akamai Technologies and more
Check out the providers earning headlines in extended trading. Yelp — Shares of the cafe evaluation internet site slid 6% as Yelp posted mild 2nd-quarter profits advice. The business described to start with-quarter earnings of 20 cents a share, surpassing analysts’ estimates of 6 cents a share, for each LSEG. Revenue for the time period […]
Read More
Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker […]
Read More
Here are the big health sector themes to watch next year
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and […]
Read More
Here’s what Wall Street is saying about obesity drug Wegovy following Novo Nordisk’s key study
Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart Association […]
Read More
Inventory futures are minor altered as traders weigh rising Treasury yields: Are living updates
Traders on the floor of the New York Inventory Trade. Ted Shaffrey | AP Inventory futures were little adjusted on Tuesday, as traders retained an eye on rising Treasury yields. Futures tied to the S&P 500 additional less than .1%, while Nasdaq 100 futures fell .1%. Dow Jones Industrial Normal futures climbed 22 points, or […]
Read More
Will weight loss drugs lead to less food consumption? Here’s what Walmart is saying
More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and Ozempic […]
Read More
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More